[摘要] 目的 观察健择与顺铂联合化疗方案(GP方案)治疗晚期非小细胞肺癌(NSCLC)的临床疗效及毒副反应。方法 对82例Ⅲ期及Ⅳ期非小细胞肺癌患者给以GP方案治疗。健择1250mg/m2静滴第1、8天，DDP 70～80mg/m2静滴第1天,21天为1个周期，每例患者至少治疗2周期。结果 全组部分缓解30例，稳定44例、进展8例；总有效率为36.6%。初治病人有效率为43.2%，复治病人有效率为28.9%。全组中位生存期9.2个月，1年生存率为37.8%。最常见的毒副反应为骨髓抑制，Ⅲ～Ⅳ度白细胞及血小板降低发生率分别为28.0%和24.4%，其余毒副反应较轻微，可以耐受。结论 健择联合顺铂化疗方案一线治疗或二线治疗晚期非小细胞肺癌均有较好疗效,毒性反应轻，患者的耐受性较好。

    [关键词] 非小细胞肺癌；健择；顺铂；化疗

    Clinical observation of gemcitabine plus cisplatin in the treatment of advanced non-small cell lung cancer

    GU Ai-qin,HAN Bao-hui,SHEN Jie,et al.

    Department of Pneumology,Shanghai Chest Hospital,Shanghai 200030,China

    [Abstract] Objective To evaluate the therapeutic effects and toxicity reaction of gemcitabine plus cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC).Methods 82 patients with NSCLC in stage Ⅲ and Ⅳ were treated with gemcitabine 1250mg/m2 by intravenous infusion on 1st and 8th days,and cisplatin 70～80mg/m2 by intravenous infusion on 1st in a 21-day cycle.Each patient was treated at least for 2 cycles.Results Of the 82 patients,30 cases got partial response,44 cases had stable disease,and 8 cases had progressive disease,with an overall response rate of 36.6%(30/82).The response rate was 43.2%(19/44) in the initial patients and 28.9%(11/38) in the retreated patients(P>0.05).The medium survivals were 9.2 months.The 1-year survival rates were 37.8%.The main toxicities were leukopenia (incidence of 28.0% for grade Ⅲ and Ⅳ) and thrombocytopenia (incidence of 24.4% for grade Ⅲ and Ⅳ).Conclusion The combination of gemcitabine and cisplatin is feasible, well-tolerated and effective scheme in either first-line or second-line treatment of advanced NSCLC. ......